FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Adrian Newman-Tancredi

Research Profile

Living Beings

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Laëtitia Lemoine; Adrian Newman-Tancredi; Bernard Vacher; Guillaume Becker; Thierry Billard; Sophie Lancelot; Luc Zimmer
Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
Laia Lladó-Pelfort; Adrian Newman-Tancredi; Francesc Artigas; Marie-Bernadette Assié; Pau Celada
In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.
Mark J Millan; O Muller; Adrian Newman-Tancredi; Clotilde Mannoury La Cour; Philippe Marin; Valérie Audinot; Joël Bockaert; Jean A Boutin; Benjamin Chanrion; Didier Cussac; Anne Dekeyne; Benjamin Di Cara; Delphine S Dupuis; Ralf JOckers; Maud Kamal; Gilbert Lavielle
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Adrian Newman-Tancredi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Laëtitia Lemoine; Adrian Newman-Tancredi; Bernard Vacher; Guillaume Becker; Thierry Billard; Sophie Lancelot; Luc Zimmer
Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(6):969-76.
2012: Laia Lladó-Pelfort; Adrian Newman-Tancredi; Francesc Artigas; Marie-Bernadette Assié; Pau Celada
In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.
Psychopharmacology 2012;221(2):261-72.
2012: Mark J Millan; O Muller; Adrian Newman-Tancredi; Clotilde Mannoury La Cour; Philippe Marin; Valérie Audinot; Joël Bockaert; Jean A Boutin; Benjamin Chanrion; Didier Cussac; Anne Dekeyne; Benjamin Di Cara; Delphine S Dupuis; Ralf JOckers; Maud Kamal; Gilbert Lavielle
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
The Journal of pharmacology and experimental therapeutics 2012;340(3):750-64.
2011: Ronan Depoortère; Mathieu Meleine; Emilie Muller; Monique Aliaga; Denis Ardid; Laurent Bardin; Adrian Newman-Tancredi
Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents.
European journal of pharmacology 2011;672(1-3):83-7.
2011: Philippe Huot; Adrian Newman-Tancredi; Susan H Fox; Jonathan M Brotchie
Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
The Journal of pharmacology and experimental therapeutics 2011;339(1):2-8.
2011: Juan Mico; Adrian Newman-Tancredi; Olivier Vitton; Laurent Bardin; Esther Berrocoso; Philippe Ladure; Ronan Depoortère
Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall-Selitto model.
Behavioural pharmacology 2011;22(5-6):599-606.
2011: Adrian Newman-Tancredi; Mark S Kleven
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.
Psychopharmacology 2011;216(4):451-73.
2011: Esther Berrocoso; Juan-Antonio Mico; Olivier Vitton; Philippe Ladure; Adrian Newman-Tancredi; Ronan Depoortère; Laurent Bardin
Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain.
European journal of pharmacology 2011;655(1-3):46-51.
2011: Isabelle Rauly-Lestienne; Fabrice Lestienne; Marie-Christine Ailhaud; Johan Binesse; Adrian Newman-Tancredi; Didier Cussac
Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference.
Cellular signalling 2011;23(1):58-64.
2010: Marie-Bernadette Assié; Laurent Bardin; Agnès L Auclair; Elisabeth Carilla-Durand; Ronan Depoortère; Wouter Koek; Mark S Kleven; Francis Colpaert; Bernard Vacher; Adrian Newman-Tancredi
F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2010;13(10):1285-98.
2010: Agnès L Auclair; Adeline Cathala; Frédéric Sarrazin; Ronan Depoortère; Pier Vincenzo Piazza; Adrian Newman-Tancredi; Umberto Spampinato
The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity.
Journal of neurochemistry 2010;114(5):1323-32.
2010: Ronan Depoortère; Agnès L Auclair; Laurent Bardin; Francis C Colpaert; Bernard Vacher; Adrian Newman-Tancredi
F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2010;20(9):641-54.
2010: L Lladó-Pelfort; M-B Assié; Adrian Newman-Tancredi; Francesc Artigas; Pau Celada
Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors.
British journal of pharmacology 2010;160(8):1929-40.
2010: Adrian Newman-Tancredi
The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
Current opinion in investigational drugs (London, England : 2000) 2010;11(7):802-12.
2010: Laëtitia Lemoine; Mathieu Verdurand; Bernard Vacher; Elodie Blanc; Didier Le Bars; Adrian Newman-Tancredi; Luc Zimmer
[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging.
European journal of nuclear medicine and molecular imaging 2010;37(3):594-605.
2010: Laurent Bardin; S Gregoire; M Aliaga; N Malfetes; O Vitton; P Ladure; Adrian Newman-Tancredi; Ronan Depoortère
Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats.
Neuroscience research 2010;66(2):135-40.
2009: Laurent Bardin; N Malfetes; Adrian Newman-Tancredi; Ronan Depoortère
Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies.
Behavioural brain research 2009;205(2):360-6.
2009: Agnès Auclair; Mark S Kleven; Catherine Barret-Grévoz; Martine Barreto; Adrian Newman-Tancredi; Ronan Depoortère
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Behavioural brain research 2009;203(2):288-95.
2009: Liesbeth A Bruins Slot; Fabrice Lestienne; Catherine Grevoz-Barret; Adrian Newman-Tancredi; Didier Cussac
F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
European journal of pharmacology 2009;620(1-3):27-35.
2009: Jean-Claude Martel; Marie-Bernadette Assié; Laurent Bardin; Ronan Depoortère; Didier Cussac; Adrian Newman-Tancredi
5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception.
British journal of pharmacology 2009;158(1):232-42.
2009: Ronan Depoortère; Laurent Bardin; Michael Rodrigues; Erika Abrial; Monique Aliaga; Adrian Newman-Tancredi
Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
Behavioural pharmacology 2009;20(4):303-11.
2009: Agnès Auclair; Joël Besnard; Adrian Newman-Tancredi; Ronan Depoortère
The five choice serial reaction time task: comparison between Sprague-Dawley and Long-Evans rats on acquisition of task, and sensitivity to phencyclidine.
Pharmacology, biochemistry, and behavior 2009;92(2):363-9.
2009: Marie-Bernadette Assié; Ouissame Mnie-Filali; Véronique Ravailhe; Christelle Benas; Marc Marien; Cécile Bétry; Luc Zimmer; Nasser Haddjeri; Adrian Newman-Tancredi
F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
European journal of pharmacology 2009;607(1-3):74-83.
2009: Adrian Newman-Tancredi; J-C Martel; M-B Assié; J Buritova; E Lauressergues; C Cosi; P Heusler; L Bruins Slot; F C Colpaert; B Vacher; D Cussac
Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist.
British journal of pharmacology 2009;156(2):338-53.
2008: Ronan Depoortère; Catherine Barret-Grévoz; Laurent Bardin; Adrian Newman-Tancredi
Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
European journal of pharmacology 2008;597(1-3):34-8.
2008: Didier Cussac; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Jean-Claude Martel; Nathalie Danty; Isabelle Rauly-Lestienne
Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
European journal of pharmacology 2008;594(1-3):32-8.
2008: Marie-Bernadette Assié; Elisabeth Carilla-Durand; Laurent Bardin; Mireille Maraval; Monique Aliaga; Nathalie Malfètes; Michèle Barbara; Adrian Newman-Tancredi
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
European journal of pharmacology 2008;592(1-3):160-6.
2008: Adrian Newman-Tancredi; Peter Heusler; Jean-Claude Martel; Anne-Marie Ormière; Nathalie Leduc; Didier Cussac
Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2008;11(3):293-307.
2008: Liesbeth A Bruins Slot; Laurent Bardin; Agnès L Auclair; Ronan Depoortere; Adrian Newman-Tancredi
Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
Behavioural pharmacology 2008;19(2):145-52.
2008: Peter Heusler; Adrian Newman-Tancredi; Timothé Loock; Didier Cussac
Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
European journal of pharmacology 2008;581(1-2):37-46.
2008: Mark J Millan; Clotilde Mannoury La Cour; Francesca Novi; Roberto Maggio; Valérie Audinot; Adrian Newman-Tancredi; Didier Cussac; Valérie Pasteau; Jean-A Boutin; T Dubuffet; Gilbert Lavielle
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
The Journal of pharmacology and experimental therapeutics 2008;324(2):587-99.
2007: Jean-Claude Martel; Nathalie Leduc; Anne-Marie Ormière; Valérie Faucillon; Nathalie Danty; Charlène Culie; Didier Cussac; Adrian Newman-Tancredi
WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors.
European journal of pharmacology 2007;574(1):15-9.
2007: Jean Louis Maurel; Jean-Marie Autin; Philippe Funes; Adrian Newman-Tancredi; Francis Colpaert; Bernard Vacher
High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity.
Journal of medicinal chemistry 2007;50(20):5024-33.
2007: Isabelle Rauly-Lestienne; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Didier Cussac
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Naunyn-Schmiedeberg's archives of pharmacology 2007;376(1-2):93-105.
2007: Adrian Newman-Tancredi; Didier Cussac; Ronan Depoortere
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
Current opinion in investigational drugs (London, England : 2000) 2007;8(7):539-54.
2007: Agnès Auclair; Alexandra Galinier; Joël Besnard; Adrian Newman-Tancredi; Ronan Depoortère
Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats.
Psychopharmacology 2007;193(1):45-54.
2007: Marie-Bernadette Assié; Laurent Bardin; Agnès Auclair; Nathalie Consul-Denjean; François Sautel; Ronan Depoortère; Adrian Newman-Tancredi
F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.
Naunyn-Schmiedeberg's archives of pharmacology 2007;375(4):241-50.
2007: Adrian Newman-Tancredi; Marie-Bernadette Assié; Jean-Claude Martel; Cristina Cosi; L Bruins Slot; Christiane Palmier; Isabelle Rauly-Lestienne; Francis Colpaert; Bernard Vacher; Didier Cussac
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
British journal of pharmacology 2007;151(2):237-52.
2007: Ronan Depoortère; Laurent Bardin; Agnès Auclair; Mark S Kleven; Eric P M Prinssen; Francis Colpaert; Bernard Vacher; Adrian Newman-Tancredi
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
British journal of pharmacology 2007;151(2):253-65.
2007: Ronan Depoortère; Agnès Auclair; Laurent Bardin; Liesbeth A Bruins Slot; Mark S Kleven; Francis Colpaert; Bernard Vacher; Adrian Newman-Tancredi
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
British journal of pharmacology 2007;151(2):266-77.
2007: Laurent Bardin; Agnès Auclair; Mark S Kleven; Eric P M Prinssen; Wouter Koek; Adrian Newman-Tancredi; Ronan Depoortère
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Behavioural pharmacology 2007;18(2):103-18.
2007: Peter Heusler; Adrian Newman-Tancredi; Annabelle Castro-Fernandez; Didier Cussac
Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
Neuropharmacology 2007;52(4):1106-13.
2007: Jean-Claude Martel; Anne-Marie Ormière; Nathalie Leduc; Marie-Bernadette Assié; Didier Cussac; Adrian Newman-Tancredi
Native rat hippocampal 5-HT1A receptors show constitutive activity.
Molecular pharmacology 2007;71(3):638-43.
2007: Stephane Cuisiat; Nathalie Bourdiol; Vincent Lacharme; Adrian Newman-Tancredi; Francis Colpaert; Bernard Vacher
Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
Journal of medicinal chemistry 2007;50(4):865-76.
2006: Marie-Bernadette Assié; Hélène Dominguez; Nathalie Consul-Denjean; Adrian Newman-Tancredi
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Naunyn-Schmiedeberg's archives of pharmacology 2006;373(6):441-50.
2006: Marie-Bernadette Assié; H Lomenech; V Ravailhe; Valérie Faucillon; Adrian Newman-Tancredi
Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat.
British journal of pharmacology 2006;149(2):170-8.
2006: Agnès Auclair; Mark S Kleven; Joël Besnard; Ronan Depoortère; Adrian Newman-Tancredi
Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):1900-9.
2006: Laurent Bardin; Mark S Kleven; Catherine Barret-Grévoz; Ronan Depoortère; Adrian Newman-Tancredi
Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):1869-79.
2006: Cristina Cosi; Elisabeth Carilla-Durand; Marie-Bernadette Assié; Anne Marie Ormiere; Mireille Maraval; Nathalie Leduc; Adrian Newman-Tancredi
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
European journal of pharmacology 2006;535(1-3):135-44.
2006: Liesbeth A Bruins Slot; Luc De Vries; Adrian Newman-Tancredi; Didier Cussac
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
European journal of pharmacology 2006;534(1-3):63-70.
2005: Liesbeth A Bruins Slot; Mark S Kleven; Adrian Newman-Tancredi
Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Neuropharmacology 2005;49(7):996-1006.
2005: Peter Heusler; Petrus J Pauwels; Thierry Wurch; Adrian Newman-Tancredi; Jan Tytgat; Francis C Colpaert; Didier Cussac
Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling.
Neuropharmacology 2005;49(7):963-76.
2005: Marie-Bernadette Assié; Nathalie Consul-Denjean; Wouter Koek; Adrian Newman-Tancredi
Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex.
Pharmacology 2005;75(2):63-8.
2005: Marie-Bernadette Assié; Véronique Ravailhe; Valérie Faucillon; Adrian Newman-Tancredi
Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
The Journal of pharmacology and experimental therapeutics 2005;315(1):265-72.
2005: Adrian Newman-Tancredi; Marie-Bernadette Assié; Nathalie Leduc; Anne-Marie Ormière; Nathalie Danty; Cristina Cosi
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2005;8(3):341-56.
2005: Mark S Kleven; Catherine Barret-Grévoz; Liesbeth A Bruins Slot; Adrian Newman-Tancredi
Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
Neuropharmacology 2005;49(2):135-43.
2005: Cristina Cosi; Aurelie Waget; Karin Rollet; Valentina Tesori; Adrian Newman-Tancredi
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Brain research 2005;1043(1-2):32-41.
2005: Laurent Bardin; Marie-Bernadette Assié; Martine Pélissou; Isabelle Royer-Urios; Adrian Newman-Tancredi; Jean-Paul Ribet; François Sautel; Wouter Koek; Francis C Colpaert
Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters.
The Journal of pharmacology and experimental therapeutics 2005;312(3):1034-42.
2005: Mark S Kleven; Marie-Bernadette Assié; Cristina Cosi; Catherine Barret-Grévoz; Adrian Newman-Tancredi
Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.
Psychopharmacology 2005;177(4):373-80.
2004: Mark J Millan; Didier Cussac; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Clotilde Mannoury La Cour; Adrian Newman-Tancredi; Jean-Louis Peglion
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):903-20.
2003: Adrian Newman-Tancredi; Jean-Michel Rivet; Didier Cussac; Manuelle Touzard; C Chaput; Laetitia Marini; Mark J Millan
Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
Naunyn-Schmiedeberg's archives of pharmacology 2003;368(3):188-99.
2003: Mark J Millan; Alain Gobert; Françoise Lejeune; Anne Dekeyne; Adrian Newman-Tancredi; Valérie Pasteau; Jean-Michel Rivet; Didier Cussac
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
The Journal of pharmacology and experimental therapeutics 2003;306(3):954-64.
2003: Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Manuelle Touzard; Mark J Millan
h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT.
British journal of pharmacology 2003;138(6):1077-84.
2002: Adrian Newman-Tancredi; Didier Cussac; Yann Quentric; Manuelle Touzard; Laurence Verrièle; Nathalie Carpentier; Mark J Millan
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):815-22.
2002: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Jean-Paul Nicolas; Frédéric De Ceuninck; Jean A Boutin; Mark J Millan
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
The Journal of pharmacology and experimental therapeutics 2002;303(2):805-14.
2002: Mark J Millan; Lisa Maiofiss; Didier Cussac; Valérie Audinot; Jean A Boutin; Adrian Newman-Tancredi
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):791-804.
2002: Valérie Audinot; Nelly Fabry; Jean-Paul Nicolas; Philippe Beauverger; Adrian Newman-Tancredi; Mark J Millan; Anne Try; Frédéric Bornancin; Emmanuel Canet; Jean A Boutin
Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors.
Cellular signalling 2002;14(10):829-37.
2002: Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Mark J Millan
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling.
Molecular pharmacology 2002;62(3):590-601.
2002: Didier Cussac; Adrian Newman-Tancredi; Delphine Duqueyroix; Valérie Pasteau; Mark J Millan
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
Molecular pharmacology 2002;62(3):578-89.
2002: Didier Cussac; Delphine Duqueyroix; Adrian Newman-Tancredi; Mark J Millan
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Psychopharmacology 2002;162(2):168-77.
2002: Mark J Millan; Adrian Newman-Tancredi; S Lochon; Manuelle Touzard; S Aubry; Valérie Audinot
Specific labelling of serotonin 5-HT(1B) receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [3H]GR125,743. A pharmacological characterization.
Pharmacology, biochemistry, and behavior 2002;71(4):589-98.
2002: Didier Cussac; Adrian Newman-Tancredi; Yann Quentric; Nathalie Carpentier; Guillaume Poissonnet; Jean-Gilles Parmentier; Solo Goldstein; Mark J Millan
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(3):242-52.
2002: Jean-Louis Peglion; Bertrand Goument; Nicole Despaux; Valérie Charlot; Hélène Giraud; Christian Nisole; Adrian Newman-Tancredi; Anne Dekeyne; Marc Bertrand; Patrick Genissel; Mark J Millan
Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols.
Journal of medicinal chemistry 2002;45(1):165-76.
2001: Adrian Newman-Tancredi; Didier Cussac; Mauricette Brocco; Jean-Michel Rivet; C Chaput; Manuelle Touzard; Valérie Pasteau; Mark J Millan
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra.
Brain research 2001;920(1-2):41-54.
2001: Adrian Newman-Tancredi; Laurence Verrièle; Manuelle Touzard; Mark J Millan
Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
European journal of pharmacology 2001;428(2):177-84.
2001: Valérie Audinot; Adrian Newman-Tancredi; Didier Cussac; M J Millan
Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;25(3):410-22.
2001: Mark J Millan; Alain Gobert; Françoise Lejeune; Adrian Newman-Tancredi; Jean-Michel Rivet; Agnès Auclair; Jean-Louis Peglion
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
The Journal of pharmacology and experimental therapeutics 2001;298(2):565-80.
2001: Mark J Millan; Adrian Newman-Tancredi; Delphine Duqueyroix; Didier Cussac
Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase.
European journal of pharmacology 2001;424(1):13-7.
2001: Mark J Millan; Adrian Newman-Tancredi; Yann Quentric; Didier Cussac
The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors.
Psychopharmacology 2001;156(1):58-62.
2001: Mark J Millan; Didier Cussac; G Milligan; C Carr; Valérie Audinot; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Mauricette Brocco; Delphine Duqueyroix; Jean-Paul Nicolas; Jean A Boutin; Adrian Newman-Tancredi
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
The Journal of pharmacology and experimental therapeutics 2001;297(3):876-87.
2001: Adrian Newman-Tancredi; C Chaput; Manuelle Touzard; Mark J Millan
Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(4):391-8.
2001: Alex Cordi; I Berque-Bestel; T Persigand; Jean-Michel Lacoste; Adrian Newman-Tancredi; Valérie Audinot; Mark J Millan
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
Journal of medicinal chemistry 2001;44(5):787-805.
2001: Adrian Newman-Tancredi; Laurence Verrièle; Mark J Millan
Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.
British journal of pharmacology 2001;132(2):518-24.
2001: Valérie Audinot; Adrian Newman-Tancredi; Mark J Millan
Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms.
Neuropharmacology 2001;40(1):57-64.
2000: Mark J Millan; Anne Dekeyne; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; G Milligan; Delphine Duqueyroix; Sylvie Girardon; J Mullot; Jean A Boutin; Jean-Paul Nicolas; A Renouard-Try; Jean-Michel Lacoste; Alex Cordi
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1192-205.
2000: Adrian Newman-Tancredi; Valérie Audinot; C Moreira; Laurence Verrièle; Mark J Millan
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.
Molecular pharmacology 2000;58(5):1042-9.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; T Dubuffet; Gilbert Lavielle
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
The Journal of pharmacology and experimental therapeutics 2000;293(3):1048-62.
2000: Alain Gobert; Jean-Michel Rivet; Françoise Lejeune; Adrian Newman-Tancredi; A Adhumeau-Auclair; Jean-Paul Nicolas; Laetitia Cistarelli; C Melon; Mark J Millan
Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
Synapse (New York, N.Y.) 2000;36(3):205-21.
2000: Didier Cussac; Adrian Newman-Tancredi; L Sezgin; Mark J Millan
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):569-72.
2000: Didier Cussac; Adrian Newman-Tancredi; J P Nicolas; J A Boutin; Mark J Millan
Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):549-54.
2000: Didier Cussac; Adrian Newman-Tancredi; L Sezgin; Mark J Millan
The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors.
European journal of pharmacology 2000;394(1):47-50.
2000: Adrian Newman-Tancredi; C Chaput; Manuelle Touzard; Mark J Millan
[(35)S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor-mediated G-protein activation in amygdala and lateral septum.
Neuropharmacology 2000;39(6):1111-3.
2000: Brian J Morris; Adrian Newman-Tancredi; V Audinot; CS Simpson; Mark J Millan
Activation of dopamine D(3) receptors induces c-fos expression in primary cultures of rat striatal neurons.
Journal of neuroscience research 2000;59(6):740-9.
2000: Mark J Millan; Alain Gobert; Jean-Michel Rivet; A Adhumeau-Auclair; Didier Cussac; Adrian Newman-Tancredi; Anne Dekeyne; Jean-Paul Nicolas; Françoise Lejeune
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
The European journal of neuroscience 2000;12(3):1079-95.
2000: Didier Cussac; Adrian Newman-Tancredi; Yann Quentric; Mark J Millan
An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(2):221-3.
2000: Mark J Millan; Adrian Newman-Tancredi; Valérie Audinot; Didier Cussac; Françoise Lejeune; Jean-Paul Nicolas; Francis Cogé; Jean-Pierre Galizzi; Jean A Boutin; Jean-Michel Rivet; Anne Dekeyne; Alain Gobert
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Synapse (New York, N.Y.) 2000;35(2):79-95.
2000: Pascal Carato; Patrick Depreux; Daniel Lesieur; M Millan; Adrian Newman-Tancredi; Marie-Claire Rettori; Daniel-Henri Caignard
Synthesis and binding studies on a new series of arylpiperazino benzazol-2-one and benzoxazin-3-one derivatives as selective D4 ligands.
Drug design and discovery 2000;17(2):173-81.
2000: Mark J Millan; Mauricette Brocco; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; L Maiofiss; S Queriaux; Nicole Despaux; Jean-Louis Peglion; Anne Dekeyne
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 2000;292(1):54-66.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; A Adhumeau; Mauricette Brocco; Jean-Paul Nicolas; Jean A Boutin; Nicole Despaux; Jean-Louis Peglion
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
The Journal of pharmacology and experimental therapeutics 2000;292(1):38-53.
1999: Mark J Millan; Mauricette Brocco; Alain Gobert; F Joly; K Bervoets; Jean-Michel Rivet; Adrian Newman-Tancredi; Valérie Audinot; S Maurel
Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.
The European journal of neuroscience 1999;11(12):4419-32.
1999: Adrian Newman-Tancredi; Jean-Michel Rivet; C Chaput; Manuelle Touzard; Laurence Verrièle; Mark J Millan
The 5HT(1A) receptor ligand, S15535, antagonises G-protein activation: a [35S]GTPgammaS and [3H]S15535 autoradiography study.
European journal of pharmacology 1999;384(2-3):111-21.
1999: Didier Cussac; Adrian Newman-Tancredi; Valérie Pasteau; Mark J Millan
Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism.
Molecular pharmacology 1999;56(5):1025-30.
1999: Mark J Millan; Alain Gobert; Valérie Audinot; Anne Dekeyne; Adrian Newman-Tancredi
Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;21(2 Suppl):61S-67S.
1999: T Dubuffet; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; A Loutz; Mark J Millan; Gilbert Lavielle
Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
Bioorganic & medicinal chemistry letters 1999;9(14):2059-64.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Mark J Millan
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(6):447-53.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Valérie Pasteau; S Gavaudan; Mark J Millan
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Molecular pharmacology 1999;55(3):564-74.
1998: Adrian Newman-Tancredi; C Chaput; Manuelle Touzard; Laurence Verrièle; Mark J Millan
Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTP gamma S and the novel, selective radioligand, [3H]-S 15535.
Annals of the New York Academy of Sciences 1998;861():263-4.
1998: Valérie Audinot; Adrian Newman-Tancredi; Alain Gobert; Jean-Michel Rivet; Mauricette Brocco; Françoise Lejeune; L Gluck; I Desposte; K Bervoets; Anne Dekeyne; Mark J Millan
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
The Journal of pharmacology and experimental therapeutics 1998;287(1):187-97.
1998: Mark J Millan; Adrian Newman-Tancredi; Mauricette Brocco; Alain Gobert; Françoise Lejeune; Valérie Audinot; Jean-Michel Rivet; rudy schreiber; Anne Dekeyne; Michael Spedding; Jean-Paul Nicolas; Jean-Louis Peglion
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
The Journal of pharmacology and experimental therapeutics 1998;287(1):167-86.
1998: Mark J Millan; rudy schreiber; Anne Dekeyne; Jean-Michel Rivet; K Bervoets; M Mavridis; Claude Sebban; S Maurel-Remy; Adrian Newman-Tancredi; Michael Spedding; O Muller; Gilbert Lavielle; Mauricette Brocco
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1356-73.
1998: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Valérie Audinot; Françoise Lejeune; Jean-Michel Rivet; Didier Cussac; Jean-Paul Nicolas; O Muller; Gilbert Lavielle
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1341-55.
1998: Adrian Newman-Tancredi; S Gavaudan; C Conte; C Chaput; Manuelle Touzard; Laurence Verrièle; Valérie Audinot; Mark J Millan
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
European journal of pharmacology 1998;355(2-3):245-56.
1998: Adrian Newman-Tancredi; Jean-Paul Nicolas; Valérie Audinot; S Gavaudan; Laurence Verrièle; Manuelle Touzard; C Chaput; N Richard; Mark J Millan
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
Naunyn-Schmiedeberg's archives of pharmacology 1998;358(2):197-206.
1998: Michael Spedding; Adrian Newman-Tancredi; Mark J Millan; Catherine Dacquet; A N Michel; E Jacoby; B Vickery; D Tallentire
Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat.
Neuropharmacology 1998;37(6):769-80.
1998: Alain Gobert; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; Laetitia Cistarelli; Mark J Millan
Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.
Neuroscience 1998;84(2):413-29.
1998: Adrian Newman-Tancredi; C Chaput; S Gavaudan; Laurence Verrièle; Mark J Millan
Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;18(5):395-8.
1998: Adrian Newman-Tancredi; Laurence Verrièle; C Chaput; Mark J Millan
Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists.
Naunyn-Schmiedeberg's archives of pharmacology 1998;357(3):205-17.
1997: Adrian Newman-Tancredi; Valérie Audinot; C Chaput; Laurence Verrièle; Mark J Millan
[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
The Journal of pharmacology and experimental therapeutics 1997;282(1):181-91.
1997: Mark J Millan; Adrian Newman-Tancredi; Jean-Michel Rivet; Mauricette Brocco; P Lacroix; Valérie Audinot; Laetitia Cistarelli; Alain Gobert
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
The Journal of pharmacology and experimental therapeutics 1997;282(1):132-47.
1997: Adrian Newman-Tancredi; C Conte; C Chaput; Laurence Verrièle; V Audinot-Bouchez; S Lochon; Gilbert Lavielle; Mark J Millan
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Naunyn-Schmiedeberg's archives of pharmacology 1997;355(6):682-8.
1997: Valérie Audinot; S Lochon; Adrian Newman-Tancredi; Gilbert Lavielle; Mark J Millan
Binding profile of the novel 5-HT1B/1D receptor antagonist, [3H]GR 125,743, in guinea-pig brain: a comparison with [3H]5-carboxamidotryptamine.
European journal of pharmacology 1997;327(2-3):247-56.
1997: Adrian Newman-Tancredi; C Conte; C Chaput; Laurence Verrièle; Mark J Millan
Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry.
Neuropharmacology 1997;36(4-5):451-9.
1997: Adrian Newman-Tancredi; C Conte; C Chaput; M Spedding; Mark J Millan
Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635.
British journal of pharmacology 1997;120(5):737-9.
1997: Françoise Lejeune; Adrian Newman-Tancredi; Valérie Audinot; Mark J Millan
Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats.
The Journal of pharmacology and experimental therapeutics 1997;280(3):1241-9.
1997: Adrian Newman-Tancredi; V Audinot-Bouchez; Alain Gobert; Mark J Millan
Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors.
European journal of pharmacology 1997;319(2-3):379-83.
1996: Adrian Newman-Tancredi; C Chaput; Laurence Verrièle; Mark J Millan
S 15535 and WAY 100,635 antagonise 5-HT-stimulated [35S]GTP gamma S binding at cloned human 5-HT1A receptors.
European journal of pharmacology 1996;307(1):107-11.
1996: Adrian Newman-Tancredi; Laurence Verrièle; C Chaput; Mark J Millan
Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H] CGP-12177 binding reveals rapid (24 hour) modulation.
Brain research bulletin 1996;41(2):93-6.
1996: Adrian Newman-Tancredi; C Chaput; L Verriele; Mark J Millan
Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.
Neuropharmacology 1996;35(1):119-21.
1995: Adrian Newman-Tancredi; Valérie Audinot; V Jacques; Jean-Louis Peglion; Mark J Millan
[3H](+)S 14297: a novel, selective radioligand at cloned human dopamine D3 receptors.
Neuropharmacology 1995;34(12):1693-6.
1995: Mark J Millan; Jean-Louis Peglion; J Vian; Jean-Michel Rivet; Mauricette Brocco; Alain Gobert; Adrian Newman-Tancredi; Catherine Dacquet; K Bervoets; Sylvie Girardon
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
The Journal of pharmacology and experimental therapeutics 1995;275(2):885-98.
1995: Mark J Millan; Valérie Audinot; C Melon; Adrian Newman-Tancredi
Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia.
European journal of pharmacology 1995;280(2):225-9.
1995: Mark J Millan; Jean-Michel Rivet; Valérie Audinot; Alain Gobert; Françoise Lejeune; Mauricette Brocco; Adrian Newman-Tancredi; S Maurel-Remy; K Bervoets
Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1418-27.
1995: Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Valérie Audinot; Adrian Newman-Tancredi; Mark J Millan
Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1032-46.
1993: H Sundaram; Adrian Newman-Tancredi; Philip G Strange
Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms.
Biochemical pharmacology 1993;45(5):1003-9.
1992: Adrian Newman-Tancredi; R Wootton; Philip G Strange
High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells.
The Biochemical journal 1992;285 ( Pt 3)():933-8.